Cellectis S.A. ALCLS
$3.12
▼ -2.96% 24H
About
Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of next-generation immunotherapies for cancer. With over 25 years of innovation, Cellectis leverages its proprietary TALEN® gene-editing technology to engineer chimeric antigen receptor (CAR) T-cells, creating "off-the-shelf" a…
SectorHealthcare
ExchangeXPAR
IndustryBiotechnology
CountryFrance
Employees224
TickerALCLS
Statistics
Market Cap$314.2M
Revenue (TTM)$84.6M
Net Income—
Net Margin—
EPS—
P/E-4.01
P/S3.71
P/B3.89
EV/EBITDA-3.00
ROE-76.3%
Dividend Yield—
Price$3.12
Data: Twelve Data · Revenue = mcap / P/S